Effectiveness of a Treatment Switch to Nevirapine plus Tenofovir and Emtricitabine (or Lamivudine) in Adults with HIV-1 Suppressed Viremia: e0128131

Background Switching subjects with persistently undetectable HIV-1 viremia under antiretroviral treatment (ART) to once-daily tenofovir/emtricitabine (or lamivudine) + nevirapine is a cost-effective and well-tolerated strategy. However, the effectiveness of this approach has not been established. Me...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2015-06, Vol.10 (6)
Main Authors: Llibre, Josep M, Bravo, Isabel, Ornelas, Arelly, Santos, Jose R, Puig, Jordi, Martin-Iguacel, Raquel, Paredes, Roger, Clotet, Bonaventura
Format: Article
Language:English
Subjects:
Human immunodeficiency virus
Human immunodeficiency virus 1
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Switching subjects with persistently undetectable HIV-1 viremia under antiretroviral treatment (ART) to once-daily tenofovir/emtricitabine (or lamivudine) + nevirapine is a cost-effective and well-tolerated strategy. However, the effectiveness of this approach has not been established. Methods We performed a retrospective study evaluating the rates of treatment failure, virological failure (VF), and variables associated, in all subjects initiating this switch combination in our clinic since 2001. Analyses were performed by a modified intention to treat, where switch due to toxicity equalled failure. The main endpoint was plasma HIV-RNA < 50 copies/mL. Results 341 patients were treated for a median of 176 (57; 308) weeks. At week 48, 306 (89.7%) subjects had HIV-1 RNA
ISSN:1932-6203
DOI:10.1371/journal.pone.0128131